Sarepta rocketed late Thursday after the FDA approved its Duchenne muscular dystrophy gene therapy for all patients age 4 and older.
Pfizer stock is struggling to retake its 200-day line despite promising updates in cancer treatment. Is PFE stock now a sell?
In the latest trading session, Pfizer (PFE) closed at $27.41, marking a +1.59% move from the previous day.